Papers/PMID:25351453
L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.
Oncology reports2015The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
L-glutamine — decreases numeric rating scale (NRS) pain intensity
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“NRS scores were significantly lower in group G than in group P at weeks 4, 5 and 6 (p=0.049, p=0.019, p=0.032, respectively; Fig. 3B).”
Quoted verbatim from L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.. - Study
- RCT
- Participants
- 40
- Dose
- 10 g orally three times a day throughout the chemoradiotherapy course
- Population
- Patients with untreated squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx or larynx receiving weekly cisplatin and docetaxel with 66-70 Gy radiation in both arms; strongest daily pain on a 0-10 NRS, reported at weeks 4, 5 and 6
L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.2015PMID:25351453Industry fundedPermalink